Navigation Links
Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results
Date:2/27/2009

penses: Cost of sales 267,235 - 267,235 Selling, general and administrative 488,063 (27,973) (1) 460,090 Research and development 110,211 (18,843) (2) 91,368 Impairment of other intangible assets 8,083 (8,083) (3) - Purchased in-process research and development (530) 530 (4) - Operating income 387,474 54,369 441,843 Interest expense 8,354 - 8,354 Interest and other income, net (23,080) (3,320) (5) (26,400) Income before income taxes 402,200 57,689 459,889 Income taxes 140,459 22,265 (6) 162,724 Net income $261,741 $35,424 $297,165 Diluted earnings per share $2.12 $2.40 Diluted weighted average shares 123,720 123,602 Notes to reconciliation of our GAAP statements of operations to our adjusted statements of operations: (1) To exclude stock-based compensation ($15,492), separation benefits ($10,459), contract termination costs ($540) and asset impairment charges ($1,482). (2) To exclude stock-based compensation ($1,442), upfront and milestone payments to partners ($8,910), separation benefits ($825), contract termination costs ($4,551) and asset impairment charges ($3,115). (3) To exclude impairment of other intangible assets. (4) To exclude purchased in-process research and development. (5) To exclude changes in fair value of financial instruments, net. (6) To reflect the tax effect of the pre-tax adjustments above at the applicable tax rates.


    Year Ended December 31
'/>"/>
SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Endo Pharmaceuticals Returns Product Rights to TRANSDUR(TM)-Sufentanil to DURECT
2. Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results and Highlights
3. Arbor Pharmaceuticals Announces the Launch of XYLAREX(TM) - A New Nonantibiotic Product for the Dietary Management of Recurrent Ear Infections in Children
4. Endo Pharmaceuticals Appoints William Montague to Board of Directors
5. Access Pharmaceuticals Closes Acquisition of MacroChem Corp.
6. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results
7. Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results
8. Transdel Pharmaceuticals, Inc. Featured on National Broadcast Television
9. Update: Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2008 Financial Results
10. Vanda Pharmaceuticals Responds to Announcement and Filing by a Group Led by Tang Capital Partners, LP
11. Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 2014 Recently, UWDress.com, a leading online supplier ... a new range of empire bridesmaid dresses to ... launched a summer promotion for these high quality items. All ... 25 to 75 percent off. , The company’s new ... offers efficient assistance on its website. It is true that ...
(Date:8/22/2014)... Worth, FL (PRWEB) August 22, 2014 Millennium ... of marijuana, resulting in a high level of drug use ... all ages fight against drug addiction and work to minimize ... highest levels of alcohol and drug addiction in history. According ... 2012, an estimated 23.9 million Americans aged 12 or older—or ...
(Date:8/22/2014)... New Orleans, LA The LSU Health New ... Advanced Education Nursing Traineeship grant to increase access ... disadvantaged, underserved and under-represented groups, as well as ... the US Department of Health and Human Services ... will serve as the grant,s project director., The ...
(Date:8/22/2014)... 22, 2014 Beat Eczema , ... can use natural methods to completely cure the eczema ... attention of Shane Michaels, prompting an investigative review. ... the skin, it can still be extremely debilitating and ... “The intense itching and pain that it causes on ...
(Date:8/22/2014)... autoimmune disease that affects 1 to 2 percent ... with pain, disability and joint disfigurements, but also ... and marital functioning. While many pharmacological advances help ... common. In addition, some patients avoid newer medications ... Because of this, there is interest in psychosocial ...
Breaking Medicine News(10 mins):Health News:Discounted Empire Bridesmaid Dresses Online At UWDress.com 2Health News:Millennium Treatment Group Sees Increase in Marijuana Use Among Youth 2Health News:Beat Eczema: Review Exposes Susan Clark’s Guide to Curing Eczema Naturally 2Health News:Study shows cognitive-behavioral coping skills training has positive effects on rheumatoid arthritis 2
... is widespread disgust and outrage expressed over the housing together ... Sebastian Wheeler, 43, and his boyfriend Victor Leslie Urquhart, ... Australia. ,The two men were convicted ... him for 20 days, before he was rescued. The pair ...
... tuberculosis, researchers say. ,A study of 131 people found ... to inhibit the growth of the bacteria causing the disease, reported ... has evaluated the effect of Vitamin D on the body's immunity ... researchers took blood from all the participants and infected with mycobacteria. ...
... Low-income African-American high school students with asthma who ... reported fewer days and nights with symptoms, ... activity, and less hospitalization for asthma during a ... students. ,Christine L. M. Joseph, M.P.H, ...
... At least eight people have died due to sunstroke in ... ,While three deaths have been reported from the ... from the districts of Balasore, Kandhamal, Kendrapada, Nuapada and Sundergarh, ... told IANS. ,We received complaints of about 53 ...
... not that killer body that the opposite sex takes into account ... if you are a man. ,To find our ... from the University of Western Australia in Crawley led by Marianne ... photographs. ,The volunteers were asked to rate attractiveness on ...
... that Alzheimers drug Donepezil may help people who have ... Berthier of the M dico-Sanitarias Research Centre in Malaga, ... ability to communicate. ,The researchers wanted to ... a condition characterised by an inability to pronounce or ...
Cached Medicine News:Health News:Outrage Against Gay PartnersInCrime Kept Together 2Health News:Web-based Asthma Program Improves Disease Management for Black Students 2
(Date:8/22/2014)... 2014 /CNW/ - On Aug. 20, at its annual ... Medical Association (CMA) voted on and approved a delegate ... medicinal cannabis. Bedrocan Cannabis Corp., a leading Canadian licensed ... motion. The CMA is quite right to ... smoking any plant material, including medicinal cannabis. While some ...
(Date:8/22/2014)...   Zacks Equity Research highlights Epizyme (Nasdaq: EPZM ... Panera (Nasdaq: PNRA - Free Report ) as the Bear ... Amicus Therapeutics (Nasdaq: FOLD - Free Report ), Sanofi (NYSE: ... - Free Report ). Here is a synopsis of ... : The biotech bull market is far from ...
(Date:8/22/2014)... , Aug. 22, 2014  Cannabis Science, ... cannabis formulation-based drug development and related consulting, is ... third international medical cannabis conference taking place at ... France , on October 22, 2014.  The ... stakeholders, such as researchers, health professionals, and patients, ...
Breaking Medicine Technology:Bedrocan Canada Statement Regarding Canadian Medical Association Motion on Smoking Marijuana 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 3
... June 13 Telmisartan, an angiotensin receptor blocker, ... been studied in clinical trials in more than 50,000 patients. ... market exposure of 34.5 million patient years. Convincing safety data ... the three long-term outcome trials ONTARGET, PRoFESS and TRANSCEND which ...
... Scientists from the Barbara Ann Karmanos Cancer Institute in ... agents used to promote bone health and inhibit resorption, may ... early stage breast cancer who take them for their anti-osteoporosis ... Society of Clinical Oncology Annual Meeting. , ...
Cached Medicine Technology:Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010 2Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010 3Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010 4Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010 5Karmanos Cancer Institute Researchers Study Bisphosphonates and Their Affect on Early Stage Breast Cancer 2Karmanos Cancer Institute Researchers Study Bisphosphonates and Their Affect on Early Stage Breast Cancer 3Karmanos Cancer Institute Researchers Study Bisphosphonates and Their Affect on Early Stage Breast Cancer 4
... Crossover system of implants and instruments provides ... posterior rod construct in the thoracic and ... system are available in three size ranges: ... can be used with the Isola, Pediatric ...
Portable ultrasound doppler system for peripheral and transcranial investigation....
Multiwindow transcranial and peripheral Doppler system....
Bi-Directional doppler volume flowmeter....
Medicine Products: